A Phase 3 interventional study of Sham control and Ranibizumab in Macular Edema (ME), sponsored by Novartis Pharmaceuticals. Completed at 61 sites in 19 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2016-05-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 23rd largest by enrollment, is one of 10 that started in 2013, is one of 25 in phase 3, and was the 50th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 10 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 181 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
39 studies in Macular Edema by Novartis: none open now, none under way, none of them phase 3. Of 37 finished, 25 (68%) have results posted.
Among the 39 studies in Macular Edema by Novartis, this one is the 18th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2013, is one of 22 in phase 3, and was the 17th registered.
Novartis’s Macular Edema studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Novartis’s 39 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
Drug: Ranibizumab
Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.
Other: Sham control
The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.
Time frame: Baseline, Month 2
Change From Baseline in BCVA in Study Eye up to Month 2
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.
Time frame: Baseline, Month 1, Month 2
Change From Baseline in Central Subfield Thickness (CSFT) in Study Eye
CSFT wasassessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.
Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Change From Baseline in Central Subfield Volume (CSFV) in Study Eye
CSFV was assessed OCT. A negative change from baseline indicates improvement.
Time frame: Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Number of Participants With Presence or Absence of Intra-retinal Fluid in Study Eye Compared to Baseline
The presence of intra-retinal fluid was assessed by OCT.
Time frame: Month 2, Month 6, Month 12
Number of Participants With Presence or Absence of Subretinal Fluid in Study Eye Compared to Baseline
The presence of subretinal fluid was assessed by OCT.
Time frame: Month 2, Month 6, Month 12
Number of Participants With Presence of Active Macular Edema (ME) Leakage
The presence of active ME leakage was assessed by fluorescein angiography (FA).
Time frame: Month 2
Number of Participants Requiring Rescue Treatment at Month 1
Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of \> 5 letters due to disease activity from baseline to Month 1.
Time frame: Month 1
Average Change From Baseline in BCVA
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.
Time frame: Baseline (BL), month 1 through month 6, month 1 through month 12
Number of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters
VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.
Time frame: Month 2, Month 6 , Month 12
Number of Participants With > 1, > 5, > 10 and > 15 Letters Loss
VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.
Time frame: Month 2, Month 6, Month 12
Number of Participants With Ranibizumab Treatments
The number of participants administered study treatments, according to treatment frequency, was assessed.
Time frame: Month 12
Number of Participants With Re-treatments
The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to Month 12, the maximum number of retreatments was 5.
Time frame: Month 6, month 12
Number of Primary Reasons for Decision to Treat by Investigator
The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.
Time frame: 12 months
A total of 181 participants were enrolled. Of these, 178 adults were randomized in a 2:1 ratio and considered for analysis. The 3 adolescent participants, non-randomized, received open-label treatment and were not included in the analyses. Therefore, the number enrolled = 181 differs from the number randomized = 178 in the participant flow.
| Milestone | Ranibizumab | Sham |
|---|---|---|
| Started | 118 | 60 |
| Full analysis set | 117 | 60 |
| Safety set | 119 | 58 |
| Completed | 106 | 50 |
| Not completed | 12 | 10 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal by subject | 1 | 6 |
| Withdrew: Adverse event | 2 | 0 |
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.
| letters | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye | 5.7 ± 0.81 | 2.9 ± 0.89 |
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.
| letters | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Month 1 (n=116,59) | 4.7 ± 0.70 | 1.4 ± 0.98 |
| Month 2 (n=114,59) | 5.8 ± 0.76 | 2.8 ± 1.05 |
CSFT wasassessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.
| micrometers (um) | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Month 1 (n=112,59) | -83.6 ± 127.45 | -14.3 ± 97.36 |
| Month 2 (n=112,59) | -82.5 ± 140.06 | -30.6 ± 102.77 |
| Month 3 (n=113,59) | -86.5 ± 136.43 | -92.2 ± 129.85 |
| Month 4 (n=109,57) | -94.5 ± 141.55 | -95.5 ± 140.68 |
| Month 5 (n=105,57) | -98.6 ± 136.28 | -107.6 ± 142.22 |
| Month 6 (n=109,54) | -110.6 ± 133.10 | -84.1 ± 137.86 |
| Month 7 (n=105,52) | -113.3 ± 130.84 | -112.9 ± 148.13 |
| Month 8 (n=105,51) | -113.1 ± 127.11 | -107.7 ± 157.40 |
| Month 9 (n=105,52) | -111.6 ± 127.99 | -116.3 ± 146.43 |
| Month 10 (n=103,50) | -114.1 ± 131.12 | -116.6 ± 147.26 |
| Month 11 (n=101,49) | -112.1 ± 124.00 | -123.5 ± 140.65 |
| Month 12 (n=103,50) | -121.0 ± 124.67 | -116.8 ± 137.99 |
CSFV was assessed OCT. A negative change from baseline indicates improvement.
| microliters (ul) | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Month 1 (n=112,59) | -0.296 ± 0.4570 | -0.032 ± 0.3969 |
| Month 2 (n=112,59) | -0.276 ± 0.5362 | -0.104 ± 0.3958 |
| Month 3 (n=113,59) | -0.322 ± 0.5812 | -0.348 ± 0.5075 |
| Month 4 (n=109,57) | -0.333 ± 0.5568 | -0.378 ± 0.5436 |
| Month 5 (n=105,57) | -0.383 ± 0.5592 | -0.401 ± 0.5893 |
| Month 6 (n=109,54) | -0.388 ± 0.5167 | -0.344 ± 0.5530 |
| Month 7 (n=105,52) | -0.438 ± 0.5267 | -0.438 ± 0.6098 |
| Month 8 (n=105,51) | -0.405 ± 0.5074 | -0.421 ± 0.6484 |
| Month 9 (n=105,52) | -0.446 ± 0.6066 | -0.444 ± 0.6210 |
| Month 10 (n=103,50) | -0.439 ± 0.6241 | -0.433 ± 0.6407 |
| Month 11 (n=101,49) | -0.406 ± 0.4871 | -0.459 ± 0.6157 |
| Month 12 (n=103,50) | -0.447 ± 0.4837 | -0.455 ± 0.5910 |
The presence of intra-retinal fluid was assessed by OCT.
| Participants | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Month 2, Absent (n=112,59) | 98 | 46 |
| Month 2, Definite (n=112,59) | 14 | 13 |
| Month 6, Absent (n=109,55) | 97 | 43 |
| Month 6, Definite (n=109,55) | 12 | 12 |
| Month 12, Absent (n=103,50) | 78 | 39 |
| Month 12, Definite (n=103,50) | 25 | 11 |
The presence of subretinal fluid was assessed by OCT.
| Participants | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Month 2, Absent (n=113,59) | 77 | 33 |
| Month 2, Definite (n=110,55) | 36 | 26 |
| Month 6, Absent (n=109,55) | 75 | 35 |
| Month 6, Definite (n=109,55) | 35 | 20 |
| Month 12, Absent (n=104,50) | 77 | 37 |
| Month 12, Definite (n=103,50) | 27 | 13 |
The presence of active ME leakage was assessed by fluorescein angiography (FA).
| Participants | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Number of Participants With Presence of Active Macular Edema (ME) Leakage | 96 | 53 |
Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of \> 5 letters due to disease activity from baseline to Month 1.
| Participants | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Number of Participants Requiring Rescue Treatment at Month 1 | 0 | 0 |
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.
| letters | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Average change from BL, month 1 through month 6 | 6.39 ± 8.405 | 4.50 ± 8.095 |
| Average change from BL, month 1 through month 12 | 7.40 ± 9.052 | 5.82 ± 8.927 |
VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.
| Participants | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Month 2, Gain of >= 15 letters (n=114,59) | 26 | 7 |
| Month 2, Gain of >= 10 letters (n=114,59) | 35 | 11 |
| Month 2, Gain of >= 5 letters (n=114,59) | 55 | 19 |
| Month 2, Gain of >= 1 letter (n=114,59) | 80 | 38 |
| Month 6, Gain of >= 15 letters (n=111,55) | 30 | 15 |
| Month 6, Gain of >= 10 letters (n=111,55) | 41 | 21 |
| Month 6, Gain of >= 5 letters (n=111,55) | 67 | 34 |
| Month 6, Gain of >= 1 letters (n=111,55) | 87 | 40 |
| Month 12, Gain of >= 15 letters (n=106,50) | 44 | 22 |
| Month 12, Gain of >= 10 letters (n=106,50) | 55 | 27 |
| Month 12, Gain of >= 5 letters (n=106,50) | 72 | 37 |
| Month 12, Gain of >= 1 letters (n=106,50) | 86 | 42 |
VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.
| Participants | Ranibizumab | Sham With Ranibizumab |
|---|---|---|
| Month 2, Loss of >1 letter (n=114,59) | 17 | 9 |
| Month 2, Loss of >5 letters (n=114,59) | 8 | 4 |
| Month 2, Loss of >10 letters (n=114,59) | 2 | 3 |
| Month 2, Loss of >15 letters (n=114,59) | 0 | 0 |
| Month 6, Loss of >1 letter (n=111,55) | 14 | 12 |
| Month 6, Loss of >5 letters (n=111,55) | 5 | 7 |
| Month 6, Loss of >10 letters (n=111,55) | 3 | 4 |
| Month 6, Loss of >15 letters (n=111,55) | 1 | 1 |
| Month 12, Loss of >= 1 letter (n=106,50) | 10 | 5 |
| Month 12, Loss of >= 5 letters (n=106,50) | 6 | 3 |
| Month 12, Loss of >= 10 letters (n=106,50) | 2 | 3 |
| Month 12, Loss of >= 15 letters (n=106,50) | 1 | 2 |
The number of participants administered study treatments, according to treatment frequency, was assessed.
| Participants | Ranibizumab | Sham With Ranibizumab | Sham Without Ranibizumab |
|---|---|---|---|
| Frequency of injections = 0 | 0 | 0 | 2 |
| Frequency of injections = 1 | 13 | 6 | 0 |
| Frequency of injections = 2 | 5 | 3 | 0 |
| Frequency of injections = 3 | 14 | 7 | 0 |
| Frequency of injections = 4 | 3 | 5 | 0 |
| Frequency of injections = 5 | 17 | 7 | 0 |
| Frequency of injections = 6 | 7 | 11 | 0 |
| Frequency of injections = 7 | 6 | 0 | 0 |
| Frequency of injections = 8 | 13 | 0 | 0 |
| Frequency of injections = 9 | 3 | 6 | 0 |
| Frequency of injections = 10 | 12 | 11 | 0 |
| Frequency of injections = 11 | 6 | 0 | 0 |
| Frequency of injections = 12 | 20 | 0 | 0 |
The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to Month 12, the maximum number of retreatments was 5.
| Participants | Ranibizumab | Sham With Ranibizumab | Sham Without Ranibizumab |
|---|---|---|---|
| Month 6, Frequency of re-treatment = 1 | 34 | 15 | 0 |
| Month 6, Frequency of re-treatment = 2 | 15 | 3 | 0 |
| Month 12, Frequency of re-treatment = 1 | 21 | 12 | 0 |
| Month 12, Frequency of re-treatment = 2 | 24 | 7 | 0 |
| Month 12, Frequency of re-treatment = 3 | 13 | 5 | 0 |
| Month 12, Frequency of re-treatment = 4 | 5 | 5 | 0 |
| Month 12, Frequency of re-treatment = 5 | 3 | 0 | 0 |
The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.
| Number of primary reasons | Ranibizumab | Sham With Ranibizumab | Sham Without Ranibizumab |
|---|---|---|---|
| Vision impairment | 38 | 22 | 0 |
| OCT abnormality | 637 | 345 | 1 |
| FA abnormality | 11 | 5 | 0 |
| Color fundus photography abnormality | 0 | 0 | 0 |
| Clinical abnormality | 3 | 0 | 0 |
| Without documentation (missing reason) | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5mg | — | 15/119 (12.6%) | 58/119 (48.7%) |
| Sham With Ranibizumab 0.5mg | — | 6/56 (10.7%) | 21/56 (37.5%) |
| Sham Without Ranibizumab 0.5mg | — | 1/2 (50%) | 0/2 (0%) |
| Event | Ranibizumab 0.5mg | Sham With Ranibizumab 0.5mg | Sham Without Ranibizumab 0.5mg |
|---|---|---|---|
| Basilar artery thrombosisNervous system disorders | 0/119 | 0/56 | 1/2 |
| Brain stem strokeNervous system disorders | 0/119 | 0/56 | 1/2 |
| Cardio-respiratory arrestCardiac disorders | 0/119 | 1/56 | 0/2 |
| Corneal oedema (Fellow treated eye)Eye disorders | 0/119 | 1/56 | 0/2 |
| GastritisGastrointestinal disorders | 0/119 | 1/56 | 0/2 |
| Pancreatitis acuteGastrointestinal disorders | 0/119 | 1/56 | 0/2 |
| HypokalaemiaMetabolism and nutrition disorders | 0/119 | 1/56 | 0/2 |
| Mobility decreasedMusculoskeletal and connective tissue disorders | 0/119 | 1/56 | 0/2 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/119 | 1/56 | 0/2 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/119 | 1/56 | 0/2 |
| Event | Ranibizumab 0.5mg | Sham With Ranibizumab 0.5mg | Sham Without Ranibizumab 0.5mg |
|---|---|---|---|
| Conjunctival haemorrhage (Study eye)Eye disorders | 11/119 | 7/56 | 0/2 |
| NasopharyngitisInfections and infestations | 12/119 | 2/56 | 0/2 |
| Visual acuity reduced (Study eye)Eye disorders | 11/119 | 3/56 | 0/2 |
| Eye pain (Study eye)Eye disorders | 10/119 | 2/56 | 0/2 |
| Macular oedema (Study eye)Eye disorders | 7/119 | 2/56 | 0/2 |
| Macular oedema (Fellow untreated eye)Eye disorders | 1/119 | 3/56 | 0/2 |
| InfluenzaInfections and infestations | 6/119 | 3/56 | 0/2 |
| Intraocular pressure increased (Study eye)Investigations | 6/119 | 3/56 | 0/2 |
| Cystoid macular oedema (Study eye)Eye disorders | 6/119 | 0/56 | 0/2 |
| Dry eye (Study eye)Eye disorders | 6/119 | 1/56 | 0/2 |
| Age, Continuous(Years) | Ranibizumab | Sham | Total |
|---|---|---|---|
| Mean | 63.5 ± 13.97 | 61.8 ± 15.55 | 62.9 ± 14.50 |
| Sex: Female, Male(Participants) | Ranibizumab | Sham | Total |
|---|---|---|---|
| Female | 45 | 23 | 68 |
| Male | 73 | 37 | 110 |
The record gives a start of Oct 2013, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab